Dear Editor,With the advent of immunomodulatory agents (IMiD), proteasome inhibitors (PI), and anti-CD38 monoclonal antibodies (MoAb), the survival outcomes of patients with multiple myeloma (MM) has improved and is expected to continue to improve [1]. Elotuzumab is a MoAb that binds to signaling lymphocytic activation molecule F7 (SLAMF7) on the surface of myeloma cells and induces natural killer cell-mediated antibody-dependent cellular cytotoxicity of SLAMF7-expressing myeloma cells [2].

亲爱的编辑，随着免疫调节剂（IMiD），蛋白酶体抑制剂（PI）和抗CD38单克隆抗体（MoAb）的出现，多发性骨髓瘤（MM）患者的生存结果有所改善，预计将继续改善[1。Elotuzumab是一种MoAb，与骨髓瘤细胞表面的信号传导淋巴细胞活化分子F7（SLAMF7）结合，并诱导表达SLAMF7的骨髓瘤细胞的自然杀伤细胞介导的抗体依赖性细胞毒性。

In the phase III ELOQUENT 2 trial, the addition of elotuzumab to lenalidomide and dexamethasone (ERd) led to the superior overall response rates (ORR), progression free survival (PFS) and overall survival (OS) compared to lenalidomide and dexamethasone in patients who had received 1–3 prior lines of therapy [LOT] [3, 4].

在III期ELOQUENT 2试验中，与来那度胺和地塞米松相比，在来那度胺和地塞米松（ERd）中加入elotuzumab可导致更高的总有效率（ORR），无进展生存期（PFS）和总生存期（OS）。接受过1-3次治疗的患者[批次][3,4]。

In the randomized phase II ELOQUENT 3 trial, the addition of elotuzumab to pomalidomide and dexamethasone (EPd) led to superior ORR, PFS and OS compared to pomalidomide and dexamethasone in patients with RRMM, about 60% of which had only received ≤3 prior LOT [5, 6]. A minority of patients derive long term disease control with elotuzumab-based regimens with 20% of patients treated with ERd in ELOQUENT 2 and about 4% of patients treated with EPd in ELOQUENT 3 remaining on treatment and being free of progression at 4 years [3, 6].

在随机II期ELOQUENT 3试验中，在RRMM患者中，与pomalidomide和地塞米松相比，在pomalidomide和地塞米松（EPd）中加入elotuzumab导致ORR，PFS和OS优于pomalidomide和地塞米松，其中约60%仅接受≤3个先前批次[5,6]。少数患者使用基于elotuzumab的方案获得长期疾病控制，其中20%的患者在雄辩2中接受ERd治疗，约4%的患者在雄辩3中接受EPd治疗，在4年时仍在接受治疗且无进展[3，6]。

CD38 is highly expressed on NK-cells, and rapid NK-cell depletion in the peripheral blood and bone marrow has been seen in patients treated with daratumumab with NK cell numbers recovering 3–6 months after daratumumab has been discontinued [7]. Hence it is plausible that the efficacy of elotuzumab-based regimens may be diminished if used immediately after daratumumab-based therapy as elotuzumab depends on NK-cell function for efficacy.

。因此，如果在基于daratumumab的治疗后立即使用，基于elotuzumab的方案的功效可能会降低，因为elotuzumab依赖于NK细胞功能的功效。

In ELO.

在ELO。

Data availability

数据可用性

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

支持本研究结果的数据可应通讯作者的要求提供。由于隐私或道德限制，这些数据无法公开。

ReferencesJoseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC, et al. Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD).

参考文献Joseph NS，Kaufman JL，Dicamillo S，Roberts D，Gupta VA，Hofmeister CC等。来那度胺，硼替佐米和地塞米松（RVD）与达拉木单抗，来那度胺，硼替佐米和地塞米松（D-RVD）治疗的标准和高危新诊断移植合格多发性骨髓瘤（NDMM）患者的反应和生存结果比较。

Blood. 2023;142:647.Article .

血。2023年；142:647。条款。

Google Scholar

谷歌学者

Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–9.Article

Collins SM，Bakan CE，Swartzel GD，Hofmeister CC，Efebera YA，Kwon H等。Elotuzumab通过CS1连接直接增强NK细胞对骨髓瘤的细胞毒性：增强NK细胞功能补充ADCC的证据。癌症免疫治疗。2013年；62:1841-9.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10:91.Article

Dimopoulos MA，Lonial S，White D，Moreau P，Weisel K，San Miguel J等人。RRMM中的Elotuzumab，来那度胺和地塞米松：3期随机ELOQUENT-2研究的最终总生存率结果。血癌J.2020；10：

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31.Article

Lonial S，Dimopoulos M，Palumbo A，White D，Grosicki S，Spicka I等。Elotuzumab治疗复发或难治性多发性骨髓瘤。；373:621–31.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22.Article

Dimopoulos MA、Dytfeld D、Grosicki S、Moreau P、Takezako N、Hori M等人。埃洛妥珠单抗联合泊马度胺和地塞米松治疗多发性骨髓瘤。《新英格兰医学杂志》2018年；379:1811-22.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023;41:568–78.Article

Dimopoulos MA，Dytfeld D，Grosicki S，Moreau P，Takezako N，Hori M等。Elotuzumab联合pomalidomide和地塞米松治疗复发/难治性多发性骨髓瘤：随机II期ELOQUENT-3试验的最终总生存分析。J临床肿瘤学。2023年；41:568-78.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.Article

。前免疫。2018年；9： 第2134条

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020;61:691–8.Article

Hoylman E，Brown A，Perissinotti AJ，Marini BL，Pianko M，Ye JC等。daratumumab和elotuzumab在复发和难治性多发性骨髓瘤中的最佳序列。白血病淋巴瘤。2020年；61:691-8.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.Article

。白血病。2019年；33:2266–75.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.Article

Kumar S，Paiva B，Anderson KC，Durie B，Landgren O，Moreau P等。国际骨髓瘤工作组关于多发性骨髓瘤反应和最小残留病评估的共识标准。柳叶刀Oncol。2016年；17： e328–46.文章

PubMed

PubMed

Google Scholar

谷歌学者

Rees MJ, Kumar S. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. Leuk Lymphoma. 2024;65:287–300.Article

Rees MJ，Kumar S.BCMA指导治疗，骨髓瘤工具箱中的新疗法，以及如何使用它们。白血病淋巴瘤。2024年；65:287–300.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Grajales-Cruz AF, Rodriguez Arocho CI, Rose A, Shapiro J, Finley-Oliver E, Shain KH, et al. Elotuzumab in combination with an immunomodulatory agent (IMID) in patients with multiple myeloma refractory to imids and/or daratumumab: a single-institution analysis. Blood. 2019;134:3183.Article .

Grajales-Cruz AF，Rodriguez-Arocho CI，Rose A，Shapiro J，Finley-Oliver E，Shain KH等。Elotuzumab联合免疫调节剂（IMID）治疗IMID和/或daratumumab难治性多发性骨髓瘤患者：单一机构分析。血。2019年；134:3183。条款。

Google Scholar

谷歌学者

Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/Black people 2022. CA Cancer J Clin. 2022;72:202–29.Article

Giaquinto AN，Miller KD，Tossas KY，Winn RA，Jemal A，Siegel RL。2022年非裔美国人/黑人癌症统计。CA癌症J临床。2022年；72:202–29.文章

PubMed

PubMed

Google Scholar

谷歌学者

Costa LJ, Hungria V, Mohty M, Mateos MV. How I treat triple-class refractory multiple myeloma. Br J Haematol. 2022;198:244–56.Article

Costa LJ，Hungria V，Mohty M，Mateos MV。我如何治疗三级难治性多发性骨髓瘤。Br J血液学。2022年；198:244–56.文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.Article

Ferreri CJ，Hildebrandt MAT，Hashmi H，Shune LO，McGuirk JP，Sborov DW等。先前BCMA靶向治疗后接受ide-cel治疗的多发性骨髓瘤患者的现实经验。血癌J.2023；13： 第117条

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Puertas B, Fernández-Sánchez A, Alejo E, Rey-Búa B, Martín-López AA, Pérez-López E, et al. A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma. Blood Adv. 2024;8:3478–87.Article

Puertas B，Fernández-Sánchez A，Alejo E，Rey-BúA B，Martín-López AA，Pérez-López E等。一个研究中心在三级难治性多发性骨髓瘤中T细胞重定向治疗的经验。血液Adv.2024；8： 3478-87.文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAcknowledgementsWe are grateful to all patients from the Mayo Clinic Cancer Center who participated in the study. RDP is a recipient of the Robert A. Winn Diversity in Clinical Trials Award Program, established by the Bristol Myers Squibb Foundation.Author informationAuthors and AffiliationsDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USARicardo D.

下载参考文献致谢我们感谢梅奥诊所癌症中心所有参与研究的患者。RDP是Bristol-Myers Squibb基金会设立的Robert a.Winn临床试验多样性奖计划的获得者。作者信息作者和附属机构美国佛罗里达州杰克逊维尔梅奥诊所癌症中心血液肿瘤学系。

Parrondo, Jamie Elliott, Andre Fernandez, Caitlin J. Flott, Diedre Arrington, Dustin Chapin, Jade Brown, Saurav Das, Vivek Roy, Asher A. Chanan-Khan & Sikander AilawadhiQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USABetsy R. LaPlantDepartment of Cancer Biology, Mayo Clinic Cancer Center, Jacksonville, FL, USAAsher A.

Parrondo，Jamie Elliott，Andre Fernandez，Caitlin J.Flott，Diedre Arrington，Dustin Chapin，Jade Brown，Saurav Das，Vivek Roy，Asher A.Chanan Khan＆Sikander Ailawadhiquitative Health Sciences，Mayo Clinic，Rochester，MN，USABetsy R.Laplant美国佛罗里达州杰克逊维尔市梅奥诊所癌症中心癌症生物学系Asher A。

Chanan-Khan & Sikander AilawadhiAuthorsRicardo D. ParrondoView author publicationsYou can also search for this author in.

Chanan Khan&Sikander AilawadhiAuthorsRicardo D.ParrondoView作者出版物您也可以在中搜索这位作者。

PubMed Google ScholarBetsy R. LaPlantView author publicationsYou can also search for this author in

PubMed Google ScholarBetsy R.LaPlantView作者出版物您也可以在

PubMed Google ScholarJamie ElliottView author publicationsYou can also search for this author in

PubMed谷歌学者Jamie ElliottView作者出版物您也可以在

PubMed Google ScholarAndre FernandezView author publicationsYou can also search for this author in

PubMed谷歌学者FernandezView作者出版物您也可以在

PubMed Google ScholarCaitlin J. FlottView author publicationsYou can also search for this author in

PubMed Google ScholarCaitlin J.FlottView作者出版物您也可以在

PubMed Google ScholarDiedre ArringtonView author publicationsYou can also search for this author in

PubMed Google ScholarDiedre Arrington查看作者出版物您也可以在

PubMed Google ScholarDustin ChapinView author publicationsYou can also search for this author in

PubMed Google ScholarDustin ChapinView作者出版物您也可以在

PubMed Google ScholarJade BrownView author publicationsYou can also search for this author in

PubMed Google ScholarJade BrownView作者出版物您也可以在

PubMed Google ScholarSaurav DasView author publicationsYou can also search for this author in

PubMed Google ScholarSaurav DasView作者出版物您也可以在

PubMed Google ScholarVivek RoyView author publicationsYou can also search for this author in

PubMed Google ScholarVivek RoyView作者出版物您也可以在

PubMed Google ScholarAsher A. Chanan-KhanView author publicationsYou can also search for this author in

PubMed Google ScholarAsher A.Chanan KhanView作者出版物您也可以在

PubMed Google ScholarSikander AilawadhiView author publicationsYou can also search for this author in

PubMed Google ScholarSikander AilawadhiView作者出版物您也可以在

PubMed Google ScholarContributionsAilawadhi, Chanan-Khan, and Parrondo designed the study. Parrondo wrote the manuscript. LaPlant performed the statistical analysis. Parrondo, Roy, Arrington, LaPlant, Flott, Fernandez, Das, Chapin, and Brown collected/analyzed the data for the study.

PubMed Google ScholarContributionsAilawadhi、ChananKhan和Parrondo设计了这项研究。帕伦多写了手稿。LaPlant进行了统计分析。Parrondo，Roy，Arrington，LaPlant，Flott，Fernandez，Das，Chapin和Brown收集/分析了研究数据。

All authors critically revised the manuscript and approved the final version.Corresponding authorCorrespondence to.

所有作者都严格修改了手稿并批准了最终版本。对应作者对应。

Sikander Ailawadhi.Ethics declarations

Sikander Ailawadhi。道德宣言

Competing interests

相互竞争的利益

BRL, JE, AF, CJF, DA, DC, JB, SD and VR have no conflicts of interest to declare. RDP serves on the advisory board for Sanofi Aventis and Astra Zeneca and has received research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen and Takeda, and has received research funding from Pharmacyclics, Cellectar and Janssen.

BRL、JE、AF、CJF、DA、DC、JB、SD和VR没有利益冲突需要申报。RDP是赛诺菲-安万特（Sanofi-Aventis）和阿斯特拉-捷利康（AstraZeneca）的顾问委员会成员，并获得了百时美施贵宝基金会和葛兰素史克（GlaxoSmithKline）的研究资助。SA为Celgene、Amgen、Janssen和Takeda提供咨询服务，并获得了Pharmacyclics、Cellectar和Janssen的研究资助。

AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage and Millennium..

AAC-K已获得Xencor Pharmacyclics，Merck，Janssen，Ascentage和Millennium的研究资助。。

Ethics approval and consent to participate

道德批准和同意参与

The study protocol and all amendments were reviewed and approved by the Institutional Review Board at Mayo Clinic Florida (IRB # 18-003574). The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki, and study site-specific regulations.

佛罗里达州梅奥诊所的机构审查委员会（IRB#18-003574）审查并批准了研究方案和所有修正案。该研究是根据国际协调良好临床实践指南，源自赫尔辛基宣言的原则以及研究地点特定的法规进行的。

All patients provided written informed consent..

所有患者均提供了书面知情同意书。。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationSupplementary Table 1Clinical Trial ProtocolRights and permissions

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。补充信息补充表1临床试验协议权利和权限

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material.

开放获取本文是根据知识共享署名非商业性NoDerivatives 4.0国际许可证授权的，该许可证允许以任何媒介或格式进行任何非商业性使用，共享，分发和复制，只要您对原始作者和来源给予适当的信任，提供知识共享许可证的链接，并指出您是否修改了许可材料。

You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

根据本许可证，您无权共享源自本文或其部分的改编材料。本文中的图像或其他第三方材料包含在文章的知识共享许可证中，除非该材料的信用额度中另有说明。如果材料未包含在文章的知识共享许可中，并且您的预期用途不受法律法规的许可或超出许可用途，则您需要直接获得版权所有者的许可。

To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/..

要查看此许可证的副本，请访问http://creativecommons.org/licenses/by-nc-nd/4.0/..

Reprints and permissionsAbout this articleCite this articleParrondo, R.D., LaPlant, B.R., Elliott, J. et al. Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

转载和许可本文引用本文Parrondo，R.D.，LaPlant，B.R.，Elliott，J。等人。elotuzumab与pomalidomide和地塞米松治疗daratumumab难治性多发性骨髓瘤的II期临床试验。

Blood Cancer J. 14, 152 (2024). https://doi.org/10.1038/s41408-024-01134-3Download citationReceived: 22 June 2024Revised: 13 August 2024Accepted: 28 August 2024Published: 05 September 2024DOI: https://doi.org/10.1038/s41408-024-01134-3Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

《血癌杂志》14152（2024）。https://doi.org/10.1038/s41408-024-01134-3Download引文收到日期：2024年6月22日修订日期：2024年8月13日接受日期：2024年8月28日发布日期：2024年9月5日OI：https://doi.org/10.1038/s41408-024-01134-3Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供